Clinical trials
Plasma Cell Leukemia clinical trials
Below are recruiting plasma cell leukemia clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+ - NCT05208307RecruitingPhase 2
Belantamab with pomalidomide and dexamethasone after high-risk myeloma transplant
This Phase 2 study tests a treatment combination (belantamab mafodotin, pomalidomide, and dexamethasone) for high-risk multiple myeloma after an autologous stem cell transplant. It aims to improve disease control in people who have certain genetic features or aggressive disease behavior.
Atlanta, GeorgiaAges 18 years+ - NCT05136807Recruiting
Quality of life study for people with MGUS or smoldering myeloma
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
Houston, TexasAges 18 years+ - NCT04879043RecruitingPhase 1/Phase 2
Safety study of HDP-101 for relapsed myeloma patients
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
Atlanta, GeorgiaAges 18 years+ - NCT04776395RecruitingPhase 2
Iberdomide to treat intermediate or high-risk smoldering myeloma
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT04643002RecruitingPhase 1/Phase 2
Isatuximab added to other drugs for relapsed myeloma
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT02726750Recruiting
Study of early plasma cell blood conditions before myeloma
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
Houston, TexasAges 18 years+ - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT07616089RecruitingPhase 1
Study of a new pill for advanced blood cancers
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
New treatment for blood cancers that have returned
This trial tests a new pill, tacabrutideg, for blood cancers that have returned or not improved after earlier treatments. It may work for patients who have already tried a type of targeted therapy called a BTK inhibitor.
Birmingham, AlabamaAges 18 years+ - NCT06820268RecruitingPhase 1
XS-04 for blood cancers that returned after treatment
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
BeijingAges 18–75 - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT06102694Recruiting
Blood test to find early signs of a transplant complication
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
TianjinAges 14–70 - NCT07110636Recruiting
Blood test for infection in immunocompromised adults
This trial tests a blood test that looks for infection by analyzing tiny bits of DNA from microbes. It may help find infections faster in people with weakened immune systems, such as transplant recipients or those with blood cancers.
San Francisco, CaliforniaAges 18 years+ - NCT06904066RecruitingPhase 1
Personalized T cell therapy for blood cancers
This trial tests a treatment that takes your own immune cells, modifies them to attack cancer cells, and gives them back to you. It is for people with certain blood cancers who have specific gene changes.
Bethesda, MarylandAges 18–120
Hear when a new Plasma Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for plasma cell leukemia?
- Yes. Clin2 currently lists 63 recruiting plasma cell leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a plasma cell leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a plasma cell leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.